Cooling caps designed to reduce hair loss in women undergoing chemotherapy for breast cancer (also known as alopecia) have been available internationally for decades but the FDA has only now, for the first time, cleared a scalp-cooling device for the U.S. market. Concerns about safety, efficacy and reimbursement have limited the availability of the technology for U.S. patients.